Results

 Cancer Treatments

These clincal trial results  for cancer treatments using superantigen already demonstrate significant improvement for most cancer patients. However, with you we go even further by getting you to action the 5 other steps to treating cancer safely.

___________________________________________________________

Brain Cancer

Hospital of Anhui Medical University 2006. 92 patients with Glioma (brain tumor), split into control group (radio and chemotherapy) and treatment group (Superantigen SEC, radio and chemotherapy) Results: CR (complete response)+ PR(partial response) of control group 32%, and treatment group 63.6%. Conclusion: Again showing 100% better result when using SEC.

General: Nasopharyngeal and lung cancer efficacy using radiation and Superantigen SEC = 90.5%

General: Chemotherapy users, enjoy a 80% improved life quality while used in conjunction with Superantigen (SEC)

___________________________________________________________

Liver Cancer

Liver Cancer Trial A clinical trial of 78 patients with Hepatocellular Carcinoma (liver cancer), 38 in treatment group and 38 in control group.

Conclusion: Achieved a 74% versus 46%, 4 year survival rate where the treatment group used Superantigen (SEC) in addition to the conventional medicine used in the control group

___________________________________________________________

Cervex cancer

Cervical Lymph Node Metastatic Carcinoma Journal of Medical Forum 2004; 25(1):17-18 120 Patients were randomly split into two groups:A and B group (60 cases each). Both of them received radiotherapy. A group was injected SEC into the metastatic lymph node. Results: CR of the metastatic lymph node was:A group 80.33%(53/60);B group70%(42/60). Conclusion:  SEC combined with radiotherapy on cervical lymph node metastatic carcinoma is advantageous

___________________________________________________________

Lung cancer

Pleural Effusion Induced by Lung cancer – Practical Clinical Medicine 2005:6 (7) :42-43 83 Patients split into 2 groups : 52 treated with SEC and 31 with Sodium Chloride (0.9%) for 4 weeks. Results: Pleural Effusion of treatment group disappeared with an effective rate of 80.8% while the rate was 19.4% in the control group. Conclusion: SEC is a safe and effective auxiliary way to treat Pleural effusion caused by lung cancer.

___________________________________________________________

Liver cancer

Liver cancer treated with TACE and SEC – Modern Medicine 2009:37 (3) :231-234 48 advanced primary liver cancer patients split into 2 groups : 24 treated (treatment group) with percutaneous TACE and SEC and 24 (control group) with just percutaneous TACE. Results: Clinical effective rate of treatment group was 83.3% versus 58.3% in the control group. Conclusion: Combined treatment SEC and TACE can improve clinical effectiveness and living standards of patients.

___________________________________________________________

Leukemia

The Curative Effect of Treating of Leukemia By HAS in Combination With Chemotherapy – Chinese Journal of Clinical Oncology 64 patients, average age of 34, treated with SEC (or HAS) and DA/HA or VDP (depending on case).

54 cases are in complete remission (CR rate is 84.3%), partial remissive is 6 cases (9.3%), and the total effective rate is 93.6%.

___________________________________________________________

HIV/AIDS

Clinical Trial Report of SAVir Oral Liquid on HIV/ AIDS – Beijing You An Hospital 2002 20 Patients – 10 treatment group (using SEC) 10 in control group. Most where weak, suffered weight loss, had diarrhoea and poor appetite low CD4 count. After 3 months most of treatment group had appetite restored and showed significant weight gain Treatment group CD4 count 84± 77 /u1, while the control group decreased 21±38 /u1. Conclusion: SEC is effective in improving patients immunity

___________________________________________________________

Immunity effects of chemo with superantigen

The effect of HAS / SEC on immunity – Chinese Journal of Clinical Oncology Among the 40 cases treated with HAS / SEC and radiotherapy and chemotherapy, LCT (14 cases), NK examination (12 cases), T cell subgroup examination (11 cases), All the immune indications are without significant decline, while pure radiotherapy and chemotherapy lead to significant decline of all immune indications, it proves that HAS can protect the patients’ immune system.

___________________________________________________________

Diabetese: Clinical Study on the Treatment Diabetes Mellitus with Superantigen Highly Agglutinative Staphylococcin (HAS) He Dachun, Jin Jiangyi, Cheng Xinbo, et al.. Acta Academiae Medicinae Suzhou 1999:19(7) Superantigen was observed in 20 Diabetes cases.Blood glucose and HbAlc decreased 30.89%. Insulin and C petide were examined in 36 other cases, which increased by 51.3%after treatment.In 40 cases, CD3 and CD4 T cells were increased by 13.2%, CD4/CD8 rose to 1.50 from 1.04 after treatment. Conclusion: It suggests that there is obvious synergic effect on Diabetes with HAS and glucose-lowering drug. The mechanism of which is worth further studying.

___________________________________________________________

Various cancer – improvements during trials

The improvement of clinical cancer symptoms after using Superantigen / HAS for a period of 30 days – Chinese Journal of Clinical l Oncology902 patients with various cancers : The improvement of clinical symptom includes pain relief, sleep improvement, appetite, body weight gain, physical capacity reinforcement, etc. Complete improvement: the symptoms disappear entirely Distinctive improvement: the majority of symptoms disappear Partial improvement: some of the symptoms disappear No improvement: the symptoms have no changes. The complete improvement rate is 4.8%, Distinctive improvement rate is 45.8%, Partial improvement rate is 48.3% Total effective rate of improvement is 99%

___________________________________________________________

Cancer Type Complete Distinctive Partial No Sum
Esophageal carcinoma 5 45 60 0 110
Gastric Cancer 5 60 76 0 141
Liver Cancer 1 25 37 3 66
Head of Pancreas 0 10 14 2 26
Nasopharyngeal Carcinoma 5 36 33 0 74
Lung Cancer 12 65 99 3 179
Breast Cancer 10 59 35 1 105
Cancer of the Cervix 6 47 26 0 79
Ovarian Cancer 0 34 34 0 68
Meninges Cancer 0 42 22 0 64
Total 44 423 436 9 912
Percentage 4.8 45.8 48.3 0.9 100

___________________________________________________________

Non-Small Cell Lung cancer

Clinical Study of 61 Non-Small Cell Lung Cancer Patients reated with Continuous Radiation and HAS / SEC Hongtu Gou Rong Li The Department of Radiation Therapy of First Clinic College of Chinese Medical University (Shenyang City 110001) 39 stage III and 22 stage IV cancer 2 groups : Treatment goup – Radiation and SEC, Control Group radiation only Treatment lasted 2 months and statistics based on tumor size Curative effect of treatment group – 77.7% and control group – 52%

cancer treatments

Academic recognition

Terms and Conditions